This open label, non-randomized, parallel group study will evaluate \[11C\]-RO5011232 as radiotracer for brain mGlu5 receptor occupancy and investigate the binding of RO49917523 to human mGlu5 brain receptor at steady-state in healthy volunteers. In Parts I, II and III, positron emission tomography (PET) assessments of specific uptake of the radiotracer and whole body dosimetry will be made after intravenous injection of \[11C\]-RO5011232. In Part IV, subjects will receive RO4917523 orally daily for 14 days while receiving three single intravenous bolus injections of \[11C\]-RO5011232. The anticipated time on study treatment is up to 4 weeks.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
56
orally daily, 14 days
\[11C\]-RO5011232 intravenously
Unnamed facility
Baltimore, Maryland, United States
Unnamed facility
Baltimore, Maryland, United States
Part I: mGlu5 receptor binding of [11C]-RO5011232 radiotracer in human brain, assessed by positron emission tomography (PET)
Time frame: approximately 6 months
Part II: Dosimetry/radiation safety of [11C]-RO5011232 assessments by whole body PET scan
Time frame: approximately 6 months
Part III: Measurement of test-retest precision of PET images of regions of interest in the human brain
Time frame: approximately 6 months
Part IV: Correlation between RO4917523 plasma concentration and R04917523 binding to mGlu5 receptor in brain
Time frame: approximately 6 months
Safety of [11C]-RO5011232 administered intravenously at microdose level: Incidence of adverse events
Time frame: approximately 6 months
Part IV: In vitro binding potential (reference region with no specific binding of radiotracer) assessed by PET
Time frame: approximately 6 months
Part IV: Safety of 14-day treatment with RO4917523: Incidence of adverse events
Time frame: approximately 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.